Sociedad Americana de Hirudoterapia

Ministeri de Salut — Govern d'Andorra

Andorra MS · Andorra · europe

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Andorra's Ministry of Health — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national pharmaceutical and medical device framework as appropriate, with practical reliance on Spanish AEMPS and French ANSM authorisations.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Andorra
Leech status
unregulated
Last ASH review
2026-05-27

Relevant Regulation Codes

  • Andorran Llei general de sanitat (Llei 20/2014, qualificada, as amended)
  • Operational reliance on Spanish AEMPS / French ANSM authorisations for medicinal products in practice

Prescriber Requirements

  • Col·legi Oficial de Metges d'Andorra–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

Catalan, Spanish or French-language labelling per local convention; standard cold-chain conditions. Products typically enter via Spanish or French customs and distribution channels.

Import/Export Rules

Andorra Departament d'Agricultura i Ramaderia clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Caixa Andorrana de Seguretat Social (CASS) coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; Andorra's small jurisdiction relies heavily on Spanish AEMPS and French ANSM authorisations in practice; whether the national legal framework would treat live-organism medical devices distinctly has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.